Sublingual allergy immunotherapy tablet for Allergic Rhinitis (MATIC Trial)

"This study is no longer recruiting patients. The listing for the clinical trial was first posted on October 12th, 2019 and edited for the last time on May 23rd, 2022. There are other active studies; as of right now, there 67 trials concerning allergic rhinitis and 2 more specifically for Sublingual allergy immunotherapy tablet admitting patients."

"There are two ongoing Phase 3 clinical trials for the Sublingual allergy immunotherapy tablet. Although most of the 145 live studies for this medication are based in Oklahoma City, Oklahoma, there is significant geographical diversity."

"Sublingual allergy immunotherapy tablet is rated a 3 for safety by our team at Power. This is because it has reached Phase 3 in clinical trials, meaning that there is both efficacy and safety data supporting its use."

"Children aged 5 to 11 can be enrolled in this clinical trial, as seen in the inclusion criteria. Out of the 72 total studies, 26 are for patients under 18 years old and 46 are for those over 65."

"This study is not currently recruiting patients. However, if you're looking for other studies to participate in, there are 67 trials for allergic rhinitis and 2 Sublingual allergy immunotherapy tablet clinical trials that are actively enrolling participants."

"Currently, there are 2 ongoing studies for Sublingual allergy immunotherapy tablet in 46 cities and 13 countries. The first clinical trial was conducted in 2018 and completed Phase 3 drug approval stages. ALK-Abelló A/S sponsored the study which enrolled 600 patients. Since then, 18293 similar trials have been run."

"63 total sites are currently participating in this trial, with locations including North York, Marietta and Miami. If you are considering joining the trial, it may be helpful to select a site near you in order to reduce travel requirements."

"1459 children between the ages of 5 and 11 who struggle with allergic rhinitis are being recruited for this study. The most important candidate requirements are as follows: they must have had AR symptoms on 8 or more days in the 2 weeks leading up to the start of the study, be either male or female, have a history of HDM AR/C (with or without asthma), and still experience allergic rhinitis symptoms even after receiving allergy medication in the year prior to screening."